MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL FOR NOVEL M1/M4 MUSCARINIC AGONIST IN DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ MapLight Therapeutics announced it has initiated a Phase 1 clinical trial evaluating ML-007, a novel therapeutic developed to target circuits.
/PRNewswire/ MapLight Therapeutics announced it has initiated a Phase 1 clinical trial evaluating ML-007, a novel therapeutic developed to target circuits.
Former Bristol Myers Squibb compatriots are reuniting at Flagship Pioneering. Natural killer cell biotech Acepodia has enlisted AbbVie oncology exec Thorsten Graef as its chief medical officer. And Centessa has called upon a former AstraZeneca heavyweight as its new CMO.